TECHWIRE 30
(CIX: WRAL30)  1,110.36    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014
(NQ: Apple)  102.50    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014
(NY: QUINTILES)  56.12    (0 %)  Updated: 06:40 PM EDT, Aug 29 2014
(OP: BASF SE)  102.90    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014
(NQ: BioCryst)  13.50    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014
(NQ: BioDelivery)  16.00    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014
(NQ: CEMP)  10.57    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014
(NQ: Cisco Systems)  24.99    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014
(NQ: Cree)  45.56    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014
(NQ: DARA)  1.25    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014
(NY: EMC CORPORATION)  29.53    (0 %)  Updated: 06:40 PM EDT, Aug 29 2014
(NQ: Extreme Networks)  5.33    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014
(NQ: FB)  74.82    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014
(NY: GLAXOSMITHKLINE)  49.10    (0 %)  Updated: 06:40 PM EDT, Aug 29 2014
(NQ: GOOG)  571.60    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014
(NY: IBM)  192.30    (0 %)  Updated: 06:40 PM EDT, Aug 29 2014
(NY: LH)  107.23    (0 %)  Updated: 06:40 PM EDT, Aug 29 2014
(OP: Lenovo Group)  30.52    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014
(NY: MRK)  60.11    (0 %)  Updated: 06:40 PM EDT, Aug 29 2014
(NQ: Microsoft Corp)  45.43    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014
(NQ: NTAP)  42.16    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014
(NY: NOVARTIS AG)  89.84    (0 %)  Updated: 06:40 PM EDT, Aug 29 2014
(OP: Novozymes A/S)  46.24    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014
(NY: PFIZER)  29.39    (0 %)  Updated: 06:40 PM EDT, Aug 29 2014
(NQ: Pozen)  8.30    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014
(NY: RED HAT)  60.92    (0 %)  Updated: 06:40 PM EDT, Aug 29 2014
(NQ: BBRY)  10.18    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014
(NQ: Salix)  159.11    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014
(NQ: SQI)  15.97    (0 %)  Updated: 08:10 PM EDT, Aug 29 2014

Posts tagged “Merck”

June 9

Premium Lock Merck to buy Idenix in $3.85 billion deal

Merck  Merck said Monday it would buy Idenix Pharmaceuticals for $3.85 billion and plans to combine the company's two most promising drugs to produce a faster, more effective cure for hepatitis C.

February 4

Premium Lock GSK, others team with NIH in $230M effort to fight Alzheimer's, other diseases

Alzheimer's Data generated from the work will be made public for other scientists to use, a move that the U.S. National Institutes of Health called groundbreaking. The targeted diseases are some of the most prevalent conditions among Americans, costing the nation billions of dollars in treatment and lost productivity.

January 9

Premium Lock Report: Novartis looks to deal vaccine, animal health businesses to Merck

Novartis reportedly is in negotiations with fellow drug giant Merck about a $10 billion asset swap that would include the Novartis human vaccines and animal health businesses. Novartis operates a huge vaccine in Holly Springs and is building an R&D center in RTP.

Novartis plant in Holly Springs Novartis plant in Holly Springs

October 28, 2013

Premium Lock Merck narrows full-year revenue forecast as key drug sales slip

Merck  Merck the second-biggest U.S. drugmaker which operates a huge facility in Durham, narrowed its full-year forecast after sales of its top-seller, diabetes pill Januvia, declined.

October 1, 2013

Premium Lock Merck to cut 8,500 more jobs, shifts its R&D efforts

Merck  The second largest U.S. drug maker, which has a large vaccine plant operation in Durham, is cutting thousands of jobs and consolidating its headquarters in New Jersey.

May 9, 2013

Premium Lock GSK, Merck slash cost of cervical cancer vaccine 95% for use in poorest countries

Vaccine Two drug giants with substantial operations in North Carolina are drastically cutting the costs of their cervical cancer vaccines as part of the first large-scale effort to get the shots to girls in the world's poorest areas.

February 15, 2013

Premium Lock Merck to pay $688M to settle suit from investors over cholesterol drugs

Merck  The deal settles two long-running lawsuits brought by investors who alleged the drugmaker delayed releasing bad news on its blockbuster cholesterol drugs to prevent a drop in sales.

Updated December 10, 2012

Premium Lock Chemistry among people, companies is crucial to biochemistry deals

Finding the right chemistry is crucial to biotech deals, as two major life science partnerships in the Triangle have shown this year: GSK and Liquidia; Merck and Chimerix.

Drug deal Drug deal

July 25, 2012

Premium Lock Merck licenses HIV compound from RTP-based Chimerix

Fighting HIV In exchange for exclusive worldwide license and funding the drug development and commercialization costs, Merck will pay Chimerix $17.5 million on top of royalties on future sales and milestone payments of up to $151 million.

May 2, 2012

Premium Lock Merck investing $15M to expand, renovate Wilson NC facility

Merck  Drug giant Merck will invest $15 million to update and expand its facility in Wilson. However, no new jobs are planned, the Wilson Times reports.

October 10, 2011

Premium Lock Merck CEO to take over as chairman Dec. 1

Merck  The drug giant also receives approval from the FDA for a drug that treats type 2 diabetes and cholesterol problems.

June 30, 2011

Premium Lock Merck to close former Inspire HQ in Raleigh, cut 51 workers

Merck  The drug giant recently purchased Raleigh-based Inspire Pharmaceuticals. In a notice filed with the state, the expected closure of Inspire's offices is made official.

May 17, 2011

Premium Lock Merck wraps up $430M Inspire deal, will close Raleigh HQ

Merck  Some company executives will be leaving the eye drug firm as it is absorbed by the pharmaceutical giant.

November 30, 2010

Premium Lock Merck names its president to replace CEO

Merck  Richard Clark will remain chairman of the drug giant when Kenneth Frazier assumes CEO role. Merck operates a vaccine manufacturing plant in Durham.

November 29, 2010

Premium Lock GSK drug reduces prostate cancer risk, FDA panel says

Prostate cancer Merck drug also receives support, but reviewers express concern about the overall benefits of the drugs.

November 17, 2010

Premium Lock Next big thing? Big cholesterol drop with new drug

Merck  An experimental Merck drug safely boosted good cholesterol to record highs while dropping bad cholesterol to unprecedented lows in a study that stunned researchers and renewed hopes for an entirely new way of lowering heart risks.

May 4, 2010

Premium Lock Rx for $$$: Pfizer, Merck report strong quarterly sales results

Merck, Pfizer report financials The drug giants, which are growing their presence in the Research Triangle region, say first-quarter sales were strong. Wyeth acquisition boosts Pfizer. But Schering-Plough acquisition costs hurt Merck profits.

Updated November 4, 2009

Premium Lock Merck swallows Schering-Plough and becomes No. 2

Merck merger The two pharma giants completed the deal after the markets closed Tuesday, and the new Merck moved up from being the No. 8 drugmaker. creating the No. 2 drug-maker

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Scroll